Active Rheumatoid Arthritis
Immunology
4
Pipeline Programs
3
Companies
2
Clinical Trials
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
1
Early DiscoveryClinical DevelopmentMarket
On Market (1)
Approved therapies currently available
ORENCIAApproved
abatacept
Bristol Myers SquibbSelective T Cell Costimulation Modulator [EPC]iv (infusion)2005
Competitive Landscape
3 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
AstellasCDP870
Bristol Myers SquibbAbatacept
Clinical Trials (2)
Total enrollment: 136 patients across 2 trials
Long-term Treatment Study of CDP870 Self-injection in Patients With Active Rheumatoid Arthritis Who Are Participating in the Long-term Treatment Studies (Study 275-08-002 or Study 275-08-004) of CDP870
Start: Jan 2011Est. completion: May 201386 patients
Phase 3Completed
A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate
Start: May 2007Est. completion: May 201050 patients
Phase 3Completed
Related Jobs in Immunology
Regulatory Affairs Manager(Immunology), Korea
AbbVie
Seoul, Seoul
2d ago
Regional Sales Trainer - Rheumatology (Mid Atlantic/Central)
AbbVie
Remote
2d ago
Field Reimbursement Manager - Rheumatology - Seattle, WA (North)
Johnson & Johnson
Seattle, Washington, United States of America
3d ago
$100K - $175K/yr
Senior Medical Science Liaison, Dermatology - Indianapolis
Johnson & Johnson
Indianapolis, Indiana, United States
3d ago
$137K - $236K/yr
Senior Area Business Specialist, Immunology - Detroit, MI - Johnson & Johnson Innovative Medicine
Johnson & Johnson
Detroit, Michigan, United States
3d ago
Senior Clinical Trial Physician, Rheumatology
Bristol Myers Squibb
Princeton - NJ - US
3d ago
$309K - $374K/yr
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
3 companies competing in this space